This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...